Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls

Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls. Analysis With 123I-FP-CIT (Datscan) and 123I-ADAM Brain SPECT

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01160263

Acronym

DOSERAL

Enrollment

Registered

2010-07-12

Start date

2012-10-31

Completion date

2014-10-31

Last updated

2015-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic Lateral Sclerosis

Keywords

ALS, serotonin, dopamine

Brief summary

The purpose of this study is to study the transporters of serotonin and dopamine in ALS patients in relation with the clinical phenotype, i.e., patients without stiffness, patients with pyramidal stiffness, patients with mixed (pyramidal and extra pyramidal) stiffness. For such a goal the investigators will use SPECT to compare the binding of two specific tracers in ALS patients and in matched healthy controls.

Detailed description

Study design This study is a prospective cross-sectional controlled multicentric clinical study in 60 ALS patients and 20 controls. Three cohorts of 20 ALS patients(patients without stiffness, patients with pyramidal stiffness, patients with mixed pyramidal and extra pyramidal stiffness) and 20 healthy controls will be included in this study Study centres 40 ALS patients and 13 controls will be included in the Paris ALS center, 20 ALS patients and 7 controls will be included in the Tours ALS center. MRI will be performed at the Neuroradiology department of salpetriere hospital (Paris) and Bretonneau hospital (Tours) SPECT will be done in the nuclear medicine center of each hospital (Paris- Tours). Study duration Per patient or control, the study will be lasted one month. The total study duration will be two years

Interventions

DRUGSPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM

123 I-FP-CIT (DATSCAN) : 185 MBq (5 mCi), 2,5 ml will be injected via an arm intravenous catheter. 123I-ADAM:185 MBq,5 ml will be injected via an arm intravenous catheter.

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

39 Years to 66 Years

Healthy volunteers

Yes

Inclusion criteria

1. Patients (men or women) * between 39 (exclusive) and 66 (inclusive) years old * with a sporadic ALS, defined, probable or laboratory possible * with a disease duration between 3 months (inclusive) and 5 years (exclusive) * treated with rilutek at 100 mg/ day since at least 1 month 2. Patients will be assigned in three groups in relation with the clinical phenotypes: * 20 patients without stiffness * 20 patients with pyramidal stiffness (spasticity patients). * 20 patients with mixed stiffness (both spasticity and rigidity). 3. Patients have to be capable of thoroughly understanding the information given; have signed the informed consent form (signature of spouse or family relative or acceptable third party is acceptable if the patient is physically unable to sign). 4. To have social insurance

Exclusion criteria

1. Patients with a FRONTO temporal dementia (according to NEARY' criteria) 2. Patients with any concomitant life-threatening disease or any disease or impairment likely to interfere with functional assessment; 3. Patients with any major evolving psychiatric disorder or major anxiety disorder according to DSM-IV criteria (APA, 1996) 4. Patients receiving treatments which could interfere with the serotonin or dopamine metabolism 5. Patients with contraindications for the dat-scan and /or ADAM scan 6. Patients with contraindications for the MRI scan. 7. Patients with previous vascular, traumatic or tumoral cerebral lesions making impossible the quantification of the tracer 8. Patients with a cancer within the past 5 9. Patients child bearing, breast feeding or in the second part of their cycle without any efficient contraceptive device or treatment 10. Patients liable not to be co-operative or comply with the trial requirements (as assessed by the investigator), or unable to be reached in the event of an emergency;

Design outcomes

Primary

Measure	Time frame
Dopamine transporter binding potential	1 month

Secondary

Measure	Time frame
Serotonin transporter binding potential	1 month
Relationships between transporter binding potential and the clinical scores	1 month

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026